GUB014295
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
AbbVie · Phase 1 · Completed · Enrollment 76
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| GUB014295 | Obesity or overweight | n/r | n/r | n/r | n/r |